

### 20<sup>™</sup> INTERNATIONAL CONGRESS OF THERAPEUTIC DRUG MONITORING AND CLINICAL TOXICOLOGY 18. - 21. 9. 2022 | CLARION CONGRESS HOTEL PRAGUE

This programme was published 20.9.2022.

Please follow congress <u>web pages</u> for actual programme.

## Days overview

	18.9		19.9	20.9	21.9
	Sunday		Monday	Tuesday	Wednesday
		9:00 - 10:00	Plenary Lecture 2: Hans Maurer	Plenary Lecture 3: Christophe Stove	Symposium 14:  PMx - Immunosuppressive Drugs Committee  Symposium 15:  Optimizing drug treatment with TDM and Pharmacogenetics; two peas in a pod
		10:00	Award 1: C.E. Pippenger Award	Award 2: Victor Armstrong Young Investigator Award	Symposium Workshop: Paracetamol overdoses
		10:30			TCI vs TDM (debate)
	Pre-Congress Symposium:  Model-informed precision dosing:  From publication to application (not included in Congress fee)	10:30 - 11:00	Coffee break	Coffee break	Coffee break
		11:00	Symposium 1: Update topic of immunosuppressive drugs TDM in organ transplantation	Symposium 8: State of the art in microsampling	Oral presentations 13: Pharmacometrics
	Session 1: Interpreting modelling literature		Symposium 2: Antiseizure medication	Symposium 9: Challenges in dosing cancer patients at the extremes of the age spectrum	Oral presentations 14: Antiinfective drugs (Methods)
	Coffee break		Oral presentations 1: Methods	Symposium 10: High Resolution Mass Spectrometry a Versatile Tool in Clinical Toxicology and Drug Monitoring	Symposium 17: YSC Symposum 2022 - Hot topics in precision medicine
			Symposium 3: TDM in the management of infections of implantable devices	Symposium 11: Therapeutic drug monitoring of the drugs used in the therapy of multiple sclerosis	Oral presentations 15: Varia
10:30	Session 2: Evaluation of pharmacometric models for MIPD: Is my model fit-for- purpose?	12:30 - 14:00	Lunch break	Lunch break	Lunch break - Oral presentations 12: Biologics
15:45					Rountable Session: Therapeutic monitoring of calcineurin inhibitors: The success story still facing non-negligible challenges (not included in Congress fee)
	Lunch break		Oral presentations 2:	Oral presentations 2: Symposium 12: Immunosuppressants Finding the therapeutic window for biologics	
	(not included-individually)  Session 3:  Clinical trial simulations: what if?	14:00 - _ 15:30	Symposium 4: Cannabis use and misuse	Oral presentations 6: Oncology	Closing Ceremony
			Oral presentations 3: Varia	Oral presentations 7: Toxicology	IATDMCT GENERAL ASSEMBLY
	Closing remarks and feedback		Symposium 5: Antibiotics	Oral presentations 8: Toxicology	Best poster and oral presentation
				Pro-con 1: Fixed dosing according to drug-label vs dose capping	Award
		15:30 - 16:00	Coffee break	Coffee break	
	Welcome Address		Oral presentations 4: Immunosuppressants	Symposium 13: Bioanalytical methods to support TDM of biologics	
	Plenary Lecture 1: Dario Cattaneo	16:00 - 18:00	Symposium 6: TDM of psychopharmaceutics	Oral presentations 9: Oncology	
16:00 - 17:45			Symposium 7: Exposure to environmental pollutants in early life	Oral presentations 10: Toxicology	
			Oral presenations 5: Antibiotics	Oral presentations 11: Antiinfectives/Various	
				Symposium 14: Model informed precision dosing of biotherapeutics	
		18:00 - 19:30			
		19:30		IATDMCT	
18:00 - 19:30	Welcome Cocktail	- 23:00		Congress Dinner	





# 18.09.2022 - SUNDAY

10.07.2022 301107(1						
TIME		Leo + Virgo	Meridian			
(all times are CEST)		(hall A) (main hall)				
8:30 - 18:30		Congress registration				
	10:30 - 12:00	Model-informed precision dosing: From publication to application (not included in Congress fee)  Session 1: Interpreting modelling literature  1. Iris Minichmayr: Introduction to population PK(/PD) models  2. J.B. Woillard: From publication to model code				
		3. Hands-on: Turn publication into model code				
	12:00 - 12:15	Coffee	break			
Pre-Congress Symposium (not included in Congress fee)	12:15 -	Session 2: Evaluation of pharmacometric models for MIPD: Is my model fit-for-purpose?				
	13:15	Michael Neely: Model validation and re-estimation     Hands-on: Model validation and re-estimation				
	13:15 - 14:00	Lunch (not included				
	14:00 - 15:30	Session 3: Clinical trial simulations: what if?  1. Sven van Dijkman: Introduction to simulations  2. Hands-on: Clinical trial simulations				
	15:30 - 15:45	Closing remarks and feedback				
Congress Opening	16:00 - 16:30		Welcome Address			
Congress Opening Session	16:30 - 17:45		Plenary Lecture 1: Dario Cattaneo Anti-infective TDM in special populations Chair: Teun van Gelder			
Social event	17:45 - 19:00	Welc Cock				



19.09.2022 - MONDAY						
⊤IN (all times a		Meridian (main hall)	Leo + Virgo (hall A)	Aquarius (hall B)	Taurus (hall C)	
8:00 - 18:00		Congress registration				
Plenary Lecture	9:00 - 10:30	Plenary Lecture 2: Hans Maurer Progress of mass spectrometry for research and practice in toxicology  (50 min + 10 min discussion)  Award 1:				
		C.E. Pippenger Award				
10:30 -	11:00		Coffee	break		
Concurrent Session	11:00 - 12:30	Chairs: Satohiro Masuda, Florian Lemaitre  1. Christoph Seger: Progress in the	Symposium 2: Antiseizure medication  Chairs: Torbjörn Tomson, Milan Grundmann  1. Torbjörn Tomson: The use of antiseizure medications during pregnancy: emphasis on drug level monitoring (25 min + 5 min discussion)  2. Ivana Kacirova, Milan Grundmann: Monitoring of antiepileptic drugs concentrations in mothers, milk, and breastfed infants during the early postpartum period (25 min + 5 min discussion)  3. Suthida Boonsom: The prediction of serum valproic acid in Thai pediatric patients with epilepsy (10 min + 5 min discussion)  4. Leonid Gordeev: Therapeutic drug monitoring (TDM) and toxic effects of valproic acid in pediatric patients (10 min + 5 min discussion)	Oral presentations 1:	Symposium 3: TDM in the management of infections of implantable devices Chairs: Philip Drennan, Indy Sandaradura  1. Deborah Marriott: Infections of implanted cardiac devices (25 min + 5 min discussion)  2. Philip Drennan: Infections of orthopedic protheses (25 min + 5 min discussion)  3. Indy Sandaradura: Relevance of plasma concentrations to biofilm exposure (25 min + 5 min discussion)	
12:30 -	14:00		Lunch	break		





Taurus						
(main hall) (hall A) (hall B) (hall C)						
Lunch break						
Symposium 5: Antibiotics						
dezda Petejova, Hundie Tesfaye Petejova: Expression of circulating						
ptic patients treated with nephrotoxic antibiotic agents 5 min + 5 min discussion)						
ve: Paediatric cystic fibrosis patients as tion benefiting from therapeutic drug led medicine dosing: recent advances						
therapeutic options, life quality and expectancy. 5 min + 5 min discussion)						
skova: Nephrotoxicity of vancomycine entation of higher therapeutic range O min + 5 min discussion)						
al presentations 5: Antibiotics						
Michael Neely, Karel Urbanek O min + 5 min discussion)						
s: Higher doses of vancomycin therapy preterm neonates may be needed: retrospective analysis						
A priori estimation of vancomycin first neonates by Machine Learning						
ini: The Meropenem Therapeutic Drug						
rget therapeutic range and the impact of renal function						
of renal function  C/MIC > 4: a potential instrument to lict efficacy of meropenem						
of renal function  C/MIC > 4: a potential instrument to lict efficacy of meropenem  sarriers and facilitators for therapeutic g of beta-lactams and ciprofloxacin in the ICU						
of renal function  C/MIC > 4: a potential instrument to lict efficacy of meropenem  sarriers and facilitators for therapeutic g of beta-lactams and ciprofloxacin in						
of renal function  C/MIC > 4: a potential instrument to lict efficacy of meropenem  larriers and facilitators for therapeutic g of beta-lactams and ciprofloxacin in the ICU  riguez-Báez: Piperacillin-tazobactam ations in Mexican patients with severe						
of renal function  C/MIC > 4: a potential instrument to lict efficacy of meropenem  darriers and facilitators for therapeutic g of beta-lactams and ciprofloxacin in the ICU  riguez-Báez: Piperacillin-tazobactam ations in Mexican patients with severe infections  tti: Comparison of equilibrium dialysis ation to measure unbound plasma						



20.09.2022 - TUESDAY							
TIME (all times are CEST)		Meridian (main hall)	Leo + Virgo (hall A)	Aquarius (hall B)	Taurus (hall C)		
8:00 - 18:00		Congress registration					
Plenary Lecture	9:00 - 10:30	Plenary Lecture 3: Christophe Stove Microsampling: what do we need to do to accelerate the implementation in routine care? Chair: Birgit Koch (50 min + 10 min discussion)  Award 2: Victor Armstrong Young Investigator Award					
10:30 -	- 11:00	Coffee break					
Concurrent Session	11:00 - 12:30	<ul> <li>(25 min + 5 min discussion)</li> <li>2. Tom Zwart: Transplantation (25 min + 5 min discussion)</li> <li>3. Birgit Koch: Microsampling to prevent side effects (25 min + 5 min discussion)</li> </ul>	Symposium 9: Challenges in dosing cancer patients at the extremes of the age spectrum  Chairs: Dirk Jan Moes, Vikram Gota  1. Vanita Noronha: Effect of agerelated impaired organ function, comorbidities, and concomitant drugs on the pharmacokinetics of antineoplastics in older patients with cancer (25 min + 5 min discussion)  2. Alwin Huitema: Dosing of anticancer agents to neonates and infants (25 min + 5 min discussion)  3. Shelby Barnett: Establishment of a national therapeutic drug monitoring programme for the treatment of challenging childhood cancer patients (25 min + 5 min discussion)	testing by LC-HR-MS/MS in cardiology (25 min + 5 min discussion) <b>2. Loralie Langman:</b> Pain	Symposium 11: Therapeutic drug monitoring of the drugs used in the therapy of multiple sclerosis  Chairs: Milan Grundmann, Hana Brozmanova  1. Veronika Pesakova; Hana Brozmanova: Development of LC-MS methods for the estimation of small molecules (fingolimod, teriflunomide) (15 min + 5 min discussion)  2. Patrik Matlak: Development of LC- MS methods for the estimation of natalizumab (15 min + 5 min discussion)  3. Zuzana Kusnirikova: Therapeutic monitoring of teriflunomide serum concentrations in patients with multiple sclerosis (20 min + 5 min discussion)  4. Ivana Kacirova: Therapeutic monitoring of whole blood concentrations of fingolimod and fingolimod phosphate in routine clinical practice (20 min + 5 min discussion)		
12:30 - 14:00			Lunch	break			



#### 20.09.2022 - TUESDAY Leo + Virgo Meridian Aquarius Taurus TIME (hall A) (all times are CEST) (main hall) (hall B) (hall C) 12:30 - 14:00 Lunch break Chairs: Vanita Noronha, David Suchy Chairs: Eric Franssen, Pavel Anzenbacher Chairs: Souleiman El Balkhi, Pascal Carato Chairs: Annick de Vries & Jeroen Hendrickx 1. Souleiman El Balkhi: Toxicological and analytical 1. Rossella Gottardo: Intentional and unintentional 1. Bénédicte Franck: Therapeutic drug monitoring of 1. Nicolas Frey: What did we learn about tocilizumab 2. Gertjan Wolbink: Finding a therapeutic in large real life cohorts: how to apply in daily clinical practice? 2. Sara Cairoli: LC-MS/MS method for TDM of exclitinib in pediatric patients with GVHD following hematopoietic stemcel transplantation 2. Maria Stornaiuolo: Optimization of hair sample pre treatment step for determination of drugs of abuse by UPLC-MS/MS 2. Erik Sveberg Dietrichs: Effects of perfluorosulfonic acids on P-glycoprotein mediated transport in the intestinal epithelial barrier 14:00 3. Nick Verougstraete: Results from a Volumetric Absorptive Microsampling (VAMS) home-sampling study for TDM of tyrosine kinase inhibitors. **3. Pascal Carato:** Synthesis, evaluation of halogenated parabens and BPA derivatives 15:30 Alexis Sauvaget: Investigation of human hepatic metabolism of propylparaben through an in vitro model comparison with methylparaben **4. Bram Agema:** Improving the tolerability of osimertinib by identifying its toxic limit **4. Christophe Stove:** Increasing confidence in a PEth 16:0/18:1 decision limit for abstinence/minor alcohol 1. Gertjan Wolbink vs. Nicolas Frey: Fixed dosing 5. Julien Robin: Assessment of endocrine disruptors exposure in professionals from an hospital using hair and urine analysis **5. Bianca Posocco:** Correlation between plasma and DBS concentrations of several oral anticancer drugs **6. Fenna de Vries:** Pharmacokinetics of brolizumab in a stage IV NSCLC patient after a single 200 mg infusion **6. Elies Zarrouk:** High resolution accurate mass (HRAM) approach for the detection of pesticides in **6. Nick Verougstraete:** First identification, chemical analysis and pharmacological characterization of the latest nitazene opioid etonitazepipne 15:30 - 16:00 Coffee break of biologics Chairs: Hundie Tesfaye, David Suchy Chairs: Eric Franssen, Pavel Anzenbacher Chairs: Blanka Koristkova, Karel Urbanek Chairs: Dirk Jan Moes and Annick de Vries Christine Snozek: Interpretation of urine drug test results: assessing clinical provider and laboratorian expertise I. Ivana Kacirova: Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-carboxymethoxymethylguanine 1. Mohsin El Amrani: Use of LC-MS to use for TDM of 1. Luci Giacomo: Determination of mitotane and biologics: both PK and anti-drug antibody (25 min + 5 min discussion) application in plasma samples Hundie Tesfaye: Therapeutic drug monitoring (TDM) of carboplatin in children: earlier study report versus evidence today TDM of biologics: further optimise QoL for patients o biologics Natalia Bordin Andriguetti: Plasma Efavirenz ncetrations are associated with CYP2B6 516T ALLELE in HIV Papua New Guineans extend drug annotation and open perspectives for molecular networking approach in toxikology 4. Jasmine Hughes: Model-based methods out-perform non-compartmental analysis for busulfan precision dosing Jessica Cusato: Neuro-HIV related inflammation: the role of pharmacokinetic and pharmacogenetic factors 5. Sascha K. Manier: Overcoming Pitfalls and hallenges During Optimization of an Automated Metabolite-Based Urine Screening Method Population Pharmacokinetics Model: A two-cer Prospective Interventional Study for the simultaneous quantification of antineoplasic drugs by HRMS 16:00 **6. Jinhui Xu:** A Risk prediction model incorporating concentrations of linezolid and metabolite for the occurrence of thrombocytopenia **6. Chadi Abbara:** Nonlinear mixed effect analysis of cytarabine degradation kinetics in acute myeloid leukemia patients blood samples **6. Matthias Julius Richter:** In vitro metabolism of the synthetic cannabinoid receptor agonists QMMSB and QMiPSB Chairs: Rob ter Heijne, Alwin Huitema 18:00 1. Dirk Jan Moes: Model informed precision dosing of 7. Xuemei Luo: Population Pharmacokinetics of Polymyxin B and Dosage Strategy in Critically III Patients 2. Joseph Ciccolini: Model informed precision dosing of biotherapeutics in oncology (25 min + 5 min discussion) therapy of chronic critically ill patients in a multidisciplinary Framework 9. Dominic MH Tong: Evaluating and improving eonatal gentamicin pharmacokinetic models usin aggregated routine clinical care data Candidate for Bed-side Therapeutic Monitoring of Vancomycin **11. Miao Yan:** Overall Therapeutic drug monitoring practice: an Asia-wide cross-sectional survey Social IATDMCT event Congress Dinner 23:00



TIME (all times are CEST)		Meridian (main hall)	Leo+Virgo (hall A)	Aquarius (hall B)	Taurus (hall C)			
7:30 - 15:30		Congress registration						
Concurrent Session	9:00 10:30	Symposium 15:  PMx - Immunosuppressive Drugs Committee  Chairs: Jean-Baptiste Woillard: Application of machine learning to prediction of immunosuppressant exposure, the example of tracrolimus (25 min + 5 min discussion)  2. Florian Lemaitre: is it still useful to perform limited sampling strategies in the era of microsampling (at least in the tecrolimus era)?  (25 min + 5 min discussion)  3. Anders Asberg: Many POPPK models are published for tacrolimus which more or less evaluation and validation. What is the level of evidence for the use of these models, can we derive guidelines for using them.  (25 min + 5 min discussion)  Oral presentations 13: Pharmacometrics  Chairs: J.B. Woillard, Sven van Dijkman  (10 min + 5 min discussion)  1. Sarah Baklouti: A methodology to de-shrink Empirical Bayes Estimates  2. Alessandro De Carlo: How modelling and simulations combined with artificial intelligence can improve precision dosing  3. J.B. Woillard: Recurrent neural network to predict the glomerular filtration rate in renal transplant patients  4. Ron Keizer; Dominic MH Tong; Jasmine Hughes: Lessons learned implementing pharmacokinetic models at the point of care  5. Midas Mulder: Ribavirin pharmacokinetics and -dynamics in transplant recipients with a chronic hepatitis E virus infection	Symposium 16: Optimizing drug treatment with TDM and Pharmacogenetics; two peas in a pod Chairs: Jesse Swen, Thorsten Lehr  1. Jennifer Martin: Personalized treatment of Tyrosine Kinase Inhibitors with TDM and Pharmacogenetics. (25 min + 5 min discussion)  2. Thorsten Lehr: Integrating Drug-Drug-Gene interactions: a Physiologically Based Pharmacokinetic approach (25 min + 5 min discussion)  3. Emmy Boerrigter: Improving the efficacy toxicity balance of anticancer drugs (25 min + 5 min discussion)  Coffee Oral presentations 14: Antiinfective drugs (Methods)  Chairs: Hana Brozmanova, Pavel Anzenbacher (7 min + 3 min discussion)  1. Zamrotul Izzah: Quantification of tenofovir, lamivudine and efavirenz in saliva using a mobile microvolume spectrophotometer	TCI vs TDM debate  Chair: Dario Cattaneo  Nick Holford & Teun van Gelder  (20 min + 20 min + 20 min discussion)  Symposium 17: YSC Symposium 2022 - Hot topics in precision medicine  Chairs: Maria Zimmermann-Kogadeeva, Kevin Plaxco  1. Maria Zimmermann-Kogadeeva: Drug-Gut microbiota interaction: Importance of microbiomics in Pharmacokinetics (25 min + 5 min discussion)	Symposium Workshop: Paracetamol overdoses  Chairs: Marieke Sturkenboom, Vanessa Steenkamp  1. Marieke Sturkenboom: Current guidelines on the treatment of paracetamol overdoses (25 min + 5 min discussion)  2. Vanessa Steenkamp: Prevention of paracetamol overdoses (25 min + 5 min discussion)  3. Marieke Sturkenboom; Vanessa Steenkamp: Clinical cases, interactive session (25 min + 5 min discussion)  Oral presentations 15: Varia  Chairs: Teun van Gelder, Ivana Kadrova (7 min + 3 min discussion)  1. Emma Ronde: Pharmacokinetics of antenatal corticosteroids in pregnancy: the influences of individual maternal co-variates  2. Kine Eide Kvitne: Short-and long-term effects of body weight, calorie-restriction, and RYGB on CYP1A2-, CYP2C19-, and CYP2C9- activity  3. Roy Lakis: Albumin in therapeutics: characterization and adjustment of post-translational modifications in commercial albumin solutions  4. Tod Kippin: Real-time therapeutic drug measurements enable drug concentration control in plasma and tissue.  5. Ivana Kacirova: TDM of antihypertensive drugs in routine clinical practice			
Session	12:30							
	Lunch break							
Concurrent Session - Lunch break	12:30 - 14:00	13:00-13:45 Round table Session: Hundie Tesfaye Therapeutic monitoring of calcineurin inhibitors: The success story still facing non-negligible challenges (not included in Congress fee)	Oral presentations 12: Biologics Chairs: Floris Loeff, Annick de Vries (10 min + 5 min discussion)  1. Floris Loeff: TDM of biologics reassures clinicians in personalised dosing  2. Bryan van den Broek: Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis  3. Patricio Más-Serrano: Variables influencing pharmacokinetics of adalimmaba in patients with inflammatory bowel disease  4. Camille Tron: Switch from intravenous to sub-cutaneous infliximab in inflammatory bowel disease: consequences from a pharmacokinetic perspective?  5. Yewel Chen: PK/PD model to support rituximab dosing strategies for pediatric patients with refractory nephrotic syndrome					
Closing Ceremony	14:00 - 15:30	Closing Remarks  IATDMCT GENERAL ASSEMBLY  Best poster and oral presentation Award						
1		+420 284 001 444	iatdmct2022@guarant.cz	www	.iatdmct2022.org			